Status:
RECRUITING
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Collaborating Sponsors:
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
Conditions:
Liver Cancer
Lung Cancer
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
Brief Summary
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various anti...
Detailed Description
1. Choose appropriate patients with advanced lung or other cancers, with written consent for this study; 2. Perform biopsy or collect cancerous effusion in thorax or abdomen to obtain TILs by standard...
Eligibility Criteria
Inclusion
- Patients with advanced cancers that failed to current available therapies;
- Life expectancy \>12 weeks;
- Adequate heart, lung, liver, kidney functions;
- Available for tumor biopsy or cancerous effusions;
- Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
Exclusion
- Had accepted gene therapy before;
- Severe virus infection such as HBV, HCV, HIV, et al; Known HIV positivity;
- Active infectious disease related to bacteria, virus, fungi, et al;
- Other severe diseases that the investigators consider not appropriate;
- Pregnant or lactating women;
- Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
- Other conditions that the investigators consider not appropriate.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2035
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04842812
Start Date
January 1 2021
End Date
January 1 2035
Last Update
June 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, China, 510260